GSK (ADR) (GSK)
Develops specialty medicines and vaccines through immune-system science and advanced technologies.
$50.52
vs last close−0.56 (−1.10%)
Something off on this page? Send us feedback.
Next report
Oct 28, 26
in 36 days
EPS estimate
$1.37
Revenue estimate
$11.97B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$0.59$1.13$1.23$1.48$0.68$1.24$1.36Pending
Estimate$0.44$1.08$1.12$1.26$0.64$1.16$1.27$1.37
Surprise+34.1%+4.6%+9.8%+17.5%+6.3%+6.9%+7.1%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$10.16B$10.04B$10.61B$11.32B$11.78B$10.30B$11.18BPending
Estimate$9.54B$9.72B$10.50B$11.04B$11.41B$10.23B$11.02B$11.97B
Surprise+6.5%+3.3%+1.1%+2.6%+3.2%+0.7%+1.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | $0.58 | — | — |
| Sep 2027 | $1.18 | — | — |
| Jun 2027 | $1.08 | — | — |
| Mar 2027 | $1.06 | — | — |
| Dec 2026 | $0.59 | — | — |
| Oct 2026 | $1.37 | — | — |
| Jul 2026 | $1.27 | $1.36 | +7.1% |
| Apr 2026 | $1.16 | $1.24 | +6.9% |
| Feb 2026 | $0.64 | $0.68 | +6.3% |
| Oct 2025 | $1.26 | $1.48 | +17.5% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| May 2024 | |||
| Jan 2024 | |||
| Nov 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Feb 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | $0.58 | — | — | $9.28B | — | — | — |
| Sep 2027 | $1.18 | — | — | $9.27B | — | — | — |
| Jun 2027 | $1.08 | — | — | $8.79B | — | — | — |
| Mar 2027 | $1.06 | — | — | $8.17B | — | — | — |
| Dec 2026 | $0.59 | — | — | $9.01B | — | — | — |
| Oct 28, 2026 | $1.37 | — | — | $11.97B | — | — | — |
| Jul 28, 2026 | $1.27 | $1.36 | +7.1% | $11.02B | $11.18B | +1.4% | +3.3% |
| Apr 29, 2026 | $1.16 | $1.24 | +6.9% | $10.23B | $10.30B | +0.7% | −5.6% |
| Feb 4, 2026 | $0.64 | $0.68 | +6.3% | $11.41B | $11.78B | +3.2% | +7.3% |
| Oct 29, 2025 | $1.26 | $1.48 | +17.5% | $11.04B | $11.32B | +2.6% | +5.1% |
| Jul 30, 2025 | |||||||
| Apr 30, 2025 | |||||||
| Feb 5, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Jul 31, 2024 | |||||||
| May 1, 2024 | |||||||
| Jan 31, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Jul 26, 2023 | |||||||
| Apr 26, 2023 | |||||||
| Feb 1, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Jul 27, 2022 | |||||||
| Apr 27, 2022 | |||||||
| Feb 9, 2022 | |||||||
| Oct 27, 2021 | |||||||
| Jul 28, 2021 | |||||||
| Apr 28, 2021 | |||||||
| Feb 3, 2021 | |||||||
| Oct 28, 2020 | |||||||
| Jul 29, 2020 | |||||||
| Apr 29, 2020 | |||||||
| Feb 5, 2020 | |||||||
| Oct 30, 2019 | |||||||
| Jul 24, 2019 | |||||||
| May 1, 2019 | |||||||
| Feb 6, 2019 | |||||||
| Oct 31, 2018 | |||||||
| Jul 25, 2018 | |||||||
| Apr 25, 2018 | |||||||
| Feb 7, 2018 | |||||||
| Oct 25, 2017 | |||||||
| Jul 26, 2017 | |||||||
| Apr 26, 2017 | |||||||
| Feb 8, 2017 | |||||||
| Oct 26, 2016 | |||||||
| Jul 27, 2016 | |||||||
| Apr 27, 2016 | |||||||
| Feb 3, 2016 | |||||||
| Oct 28, 2015 | |||||||
| Jul 29, 2015 |